AMI Pharm South Korea

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat ReductionView original content:https://www.prnewswire.co.uk/news-releases/ami-pharms-ayp-101-shows-promise-in-phase-2-trial-signaling-a-breakthrough-in-nonsurgical-fat-reduction-302540690.html